OA12099A - 4-Carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinolinecrystal as CETP inhibitor. - Google Patents

4-Carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinolinecrystal as CETP inhibitor. Download PDF

Info

Publication number: OA12099A
Authority: OA; OAPI
Prior art keywords: crystal; trifluoromethyl; formula; quinoline; carboxylic acid
Prior art date: 1999-11-30

Application number

OA1200200158A

Other languages

English (en)

Inventor

Douglas John Meldrum Allen

Troy Anthony Appleton

Lyle Robinson Brostrom

Derek Lawrence Tickner

Original Assignee

Prifzer Products Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-11-30

Filing date

2000-11-14

Publication date

2006-05-04

2000-11-14 Application filed by Prifzer Products Inc filed Critical Prifzer Products Inc

2006-05-04 Publication of OA12099A publication Critical patent/OA12099A/en

Links

239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 title abstract description 3
229940125881 cholesteryl ester transfer protein inhibitor Drugs 0.000 title abstract description 3
239000013078 crystal Substances 0.000 claims abstract description 74
238000000034 method Methods 0.000 claims abstract description 43
241000124008 Mammalia Species 0.000 claims description 56
150000001875 compounds Chemical class 0.000 claims description 37
239000008194 pharmaceutical composition Substances 0.000 claims description 35
239000003085 diluting agent Substances 0.000 claims description 26
239000003981 vehicle Substances 0.000 claims description 25
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 23
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 20
239000003937 drug carrier Substances 0.000 claims description 18
201000001320 Atherosclerosis Diseases 0.000 claims description 16
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
-1 3,5-bis- trifluoromethyl-benzyl Chemical group 0.000 claims description 15
208000000563 Hyperlipoproteinemia Type II Diseases 0.000 claims description 15
201000001386 familial hypercholesterolemia Diseases 0.000 claims description 15
HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 claims description 14
208000024172 Cardiovascular disease Diseases 0.000 claims description 9
208000032928 Dyslipidaemia Diseases 0.000 claims description 9
208000035150 Hypercholesterolemia Diseases 0.000 claims description 9
208000017170 Lipid metabolism disease Diseases 0.000 claims description 9
208000008589 Obesity Diseases 0.000 claims description 9
235000020824 obesity Nutrition 0.000 claims description 9
208000037803 restenosis Diseases 0.000 claims description 9
206010002383 Angina Pectoris Diseases 0.000 claims description 8
206010021024 Hypolipidaemia Diseases 0.000 claims description 8
208000018262 Peripheral vascular disease Diseases 0.000 claims description 8
206010063837 Reperfusion injury Diseases 0.000 claims description 8
208000006575 hypertriglyceridemia Diseases 0.000 claims description 8
208000029498 hypoalphalipoproteinemia Diseases 0.000 claims description 8
238000004519 manufacturing process Methods 0.000 claims description 8
230000002792 vascular Effects 0.000 claims description 8
206010020772 Hypertension Diseases 0.000 claims description 7
102100024640 Low-density lipoprotein receptor Human genes 0.000 claims description 7
208000006011 Stroke Diseases 0.000 claims description 7
206010045261 Type IIa hyperlipidaemia Diseases 0.000 claims description 7
208000028867 ischemia Diseases 0.000 claims description 7
238000002156 mixing Methods 0.000 claims description 7
208000010125 myocardial infarction Diseases 0.000 claims description 7
208000031225 myocardial ischemia Diseases 0.000 claims description 6
238000000634 powder X-ray diffraction Methods 0.000 claims description 6
208000037487 Endotoxemia Diseases 0.000 claims description 5
206010061216 Infarction Diseases 0.000 claims description 2
WGLUDAOFIMTWAM-WKOQGQMTSA-N ethanol;ethyl (2r,4s)-4-[[3,5-bis(trifluoromethyl)phenyl]methyl-methoxycarbonylamino]-2-ethyl-6-(trifluoromethyl)-3,4-dihydro-2h-quinoline-1-carboxylate Chemical compound CCO.COC(=O)N([C@H]1C[C@@H](CC)N(C2=CC=C(C=C21)C(F)(F)F)C(=O)OCC)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 WGLUDAOFIMTWAM-WKOQGQMTSA-N 0.000 claims description 2
230000007574 infarction Effects 0.000 claims description 2
239000002243 precursor Substances 0.000 claims 3
SGPGESCZOCHFCL-UHFFFAOYSA-N Tilisolol hydrochloride Chemical compound [Cl-].C1=CC=C2C(=O)N(C)C=C(OCC(O)C[NH2+]C(C)(C)C)C2=C1 SGPGESCZOCHFCL-UHFFFAOYSA-N 0.000 claims 2
GZVVNAWGGPWOOK-UHFFFAOYSA-N ethyl 2h-quinoline-1-carboxylate Chemical compound C1=CC=C2N(C(=O)OCC)CC=CC2=C1 GZVVNAWGGPWOOK-UHFFFAOYSA-N 0.000 claims 2
239000010685 fatty oil Substances 0.000 claims 2
KEWSCDNULKOKTG-UHFFFAOYSA-N 4-cyano-4-ethylsulfanylcarbothioylsulfanylpentanoic acid Chemical compound CCSC(=S)SC(C)(C#N)CCC(O)=O KEWSCDNULKOKTG-UHFFFAOYSA-N 0.000 claims 1
102100037637 Cholesteryl ester transfer protein Human genes 0.000 claims 1
101000880514 Homo sapiens Cholesteryl ester transfer protein Proteins 0.000 claims 1
230000002401 inhibitory effect Effects 0.000 claims 1
230000002107 myocardial effect Effects 0.000 claims 1
125000006493 trifluoromethyl benzyl group Chemical group 0.000 claims 1
239000000203 mixture Substances 0.000 abstract description 25
241000282414 Homo sapiens Species 0.000 description 41
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
239000003112 inhibitor Substances 0.000 description 17
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
239000000243 solution Substances 0.000 description 14
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 12
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
239000007787 solid Substances 0.000 description 11
229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 10
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 10
102000012336 Cholesterol Ester Transfer Proteins Human genes 0.000 description 9
108010061846 Cholesterol Ester Transfer Proteins Proteins 0.000 description 9
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 9
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
239000000843 powder Substances 0.000 description 9
238000005160 1H NMR spectroscopy Methods 0.000 description 8
108010010234 HDL Lipoproteins Proteins 0.000 description 8
102000015779 HDL Lipoproteins Human genes 0.000 description 8
208000029078 coronary artery disease Diseases 0.000 description 8
239000000463 material Substances 0.000 description 8
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 8
239000002002 slurry Substances 0.000 description 8
238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 7
238000002072 distortionless enhancement with polarization transfer spectrum Methods 0.000 description 7
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
229940093499 ethyl acetate Drugs 0.000 description 6
235000019439 ethyl acetate Nutrition 0.000 description 6
239000000706 filtrate Substances 0.000 description 6
229910052757 nitrogen Inorganic materials 0.000 description 6
239000003921 oil Substances 0.000 description 6
235000019198 oils Nutrition 0.000 description 6
108010007622 LDL Lipoproteins Proteins 0.000 description 5
102000007330 LDL Lipoproteins Human genes 0.000 description 5
150000002632 lipids Chemical class 0.000 description 5
239000000047 product Substances 0.000 description 5
239000002904 solvent Substances 0.000 description 5
238000003756 stirring Methods 0.000 description 5
HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 4
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
238000002441 X-ray diffraction Methods 0.000 description 4
239000003613 bile acid Substances 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
239000012267 brine Substances 0.000 description 4
239000002775 capsule Substances 0.000 description 4
229910052799 carbon Inorganic materials 0.000 description 4
239000003153 chemical reaction reagent Substances 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
239000002552 dosage form Substances 0.000 description 4
230000000694 effects Effects 0.000 description 4
229940125753 fibrate Drugs 0.000 description 4
238000001914 filtration Methods 0.000 description 4
229960003512 nicotinic acid Drugs 0.000 description 4
235000001968 nicotinic acid Nutrition 0.000 description 4
239000011664 nicotinic acid Substances 0.000 description 4
KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 4
238000000524 positive electrospray ionisation mass spectrometry Methods 0.000 description 4
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
239000000725 suspension Substances 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
FJLGEFLZQAZZCD-MCBHFWOFSA-N (3R,5S)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-MCBHFWOFSA-N 0.000 description 3
WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 3
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 3
XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 3
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 3
108010023302 HDL Cholesterol Proteins 0.000 description 3
241000282412 Homo Species 0.000 description 3
PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 3
238000005481 NMR spectroscopy Methods 0.000 description 3
239000007832 Na2SO4 Substances 0.000 description 3
TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 3
RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 3
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
229960005370 atorvastatin Drugs 0.000 description 3
230000000875 corresponding effect Effects 0.000 description 3
201000010099 disease Diseases 0.000 description 3
238000004090 dissolution Methods 0.000 description 3
AZFYCLSCZLWMBW-PWSUYJOCSA-N ethyl (2r,4s)-4-amino-2-ethyl-6-(trifluoromethyl)-3,4-dihydro-2h-quinoline-1-carboxylate Chemical compound FC(F)(F)C1=CC=C2N(C(=O)OCC)[C@H](CC)C[C@H](N)C2=C1 AZFYCLSCZLWMBW-PWSUYJOCSA-N 0.000 description 3
229960003765 fluvastatin Drugs 0.000 description 3
235000003599 food sweetener Nutrition 0.000 description 3
125000005456 glyceride group Chemical group 0.000 description 3
239000003456 ion exchange resin Substances 0.000 description 3
229920003303 ion-exchange polymer Polymers 0.000 description 3
229960004844 lovastatin Drugs 0.000 description 3
PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical group C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 3
QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 3
229910052943 magnesium sulfate Inorganic materials 0.000 description 3
235000019341 magnesium sulphate Nutrition 0.000 description 3
VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 3
238000010899 nucleation Methods 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
229960002965 pravastatin Drugs 0.000 description 3
TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 3
229920006395 saturated elastomer Polymers 0.000 description 3
229960002855 simvastatin Drugs 0.000 description 3
RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 3
229910052938 sodium sulfate Inorganic materials 0.000 description 3
235000011152 sodium sulphate Nutrition 0.000 description 3
239000003765 sweetening agent Substances 0.000 description 3
239000003826 tablet Substances 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
229920002261 Corn starch Polymers 0.000 description 2
229910004373 HOAc Inorganic materials 0.000 description 2
108010028554 LDL Cholesterol Proteins 0.000 description 2
238000008214 LDL Cholesterol Methods 0.000 description 2
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
108010062497 VLDL Lipoproteins Proteins 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
239000002253 acid Substances 0.000 description 2
HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
230000037396 body weight Effects 0.000 description 2
230000000747 cardiac effect Effects 0.000 description 2
GPUADMRJQVPIAS-QCVDVZFFSA-M cerivastatin sodium Chemical compound [Na+].COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 GPUADMRJQVPIAS-QCVDVZFFSA-M 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000004296 chiral HPLC Methods 0.000 description 2
FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 2
239000008120 corn starch Substances 0.000 description 2
230000002596 correlated effect Effects 0.000 description 2
230000034994 death Effects 0.000 description 2
231100000517 death Toxicity 0.000 description 2
238000001035 drying Methods 0.000 description 2
CMSGWTNRGKRWGS-UHFFFAOYSA-N ethyl 4-[[3,5-bis(trifluoromethyl)phenyl]methyl-methoxycarbonylamino]-2-ethyl-6-(trifluoromethyl)-3,4-dihydro-2h-quinoline-1-carboxylate Chemical compound C12=CC(C(F)(F)F)=CC=C2N(C(=O)OCC)C(CC)CC1N(C(=O)OC)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 CMSGWTNRGKRWGS-UHFFFAOYSA-N 0.000 description 2
125000004494 ethyl ester group Chemical group 0.000 description 2
238000009472 formulation Methods 0.000 description 2
230000004927 fusion Effects 0.000 description 2
238000009499 grossing Methods 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
239000012442 inert solvent Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
238000000386 microscopy Methods 0.000 description 2
HVOAACKKZXUIKP-UHFFFAOYSA-N n-[1-(benzotriazol-1-yl)propyl]-4-(trifluoromethyl)aniline Chemical compound N1=NC2=CC=CC=C2N1C(CC)NC1=CC=C(C(F)(F)F)C=C1 HVOAACKKZXUIKP-UHFFFAOYSA-N 0.000 description 2
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
238000001953 recrystallisation Methods 0.000 description 2
235000017557 sodium bicarbonate Nutrition 0.000 description 2
229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
238000012546 transfer Methods 0.000 description 2
YONLFQNRGZXBBF-ZIAGYGMSSA-N (2r,3r)-2,3-dibenzoyloxybutanedioic acid Chemical compound O([C@@H](C(=O)O)[C@@H](OC(=O)C=1C=CC=CC=1)C(O)=O)C(=O)C1=CC=CC=C1 YONLFQNRGZXBBF-ZIAGYGMSSA-N 0.000 description 1
AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical compound CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
MVODTGURFNTEKX-UHFFFAOYSA-N 2-bromo-n-(2-bromoethyl)-n-(thiophen-2-ylmethyl)ethanamine;hydrobromide Chemical compound Br.BrCCN(CCBr)CC1=CC=CS1 MVODTGURFNTEKX-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
241000167854 Bourreria succulenta Species 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
241000283707 Capra Species 0.000 description 1
OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
108010004103 Chylomicrons Proteins 0.000 description 1
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
241000233866 Fungi Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
241001494479 Pecora Species 0.000 description 1
102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 1
108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 1
241000288906 Primates Species 0.000 description 1
229920001800 Shellac Polymers 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
239000012190 activator Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
238000007605 air drying Methods 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
230000004075 alteration Effects 0.000 description 1
230000000879 anti-atherosclerotic effect Effects 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
230000006399 behavior Effects 0.000 description 1
QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
239000012964 benzotriazole Substances 0.000 description 1
YGBQZFPEMRCQRY-UHFFFAOYSA-N benzyl n-ethenylcarbamate Chemical compound C=CNC(=O)OCC1=CC=CC=C1 YGBQZFPEMRCQRY-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
235000019693 cherries Nutrition 0.000 description 1
239000007958 cherry flavor Substances 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
238000000576 coating method Methods 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
239000012043 crude product Substances 0.000 description 1
239000012045 crude solution Substances 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
235000001434 dietary modification Nutrition 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
239000013583 drug formulation Substances 0.000 description 1
238000002651 drug therapy Methods 0.000 description 1
239000003480 eluent Substances 0.000 description 1
XRHSGPZKFZCFQU-ZFNKBKEPSA-N ethyl (2r,4s)-4-[[3,5-bis(trifluoromethyl)phenyl]methylamino]-2-ethyl-6-(trifluoromethyl)-3,4-dihydro-2h-quinoline-1-carboxylate;4-methylbenzenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.N([C@H]1C[C@@H](CC)N(C2=CC=C(C=C21)C(F)(F)F)C(=O)OCC)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 XRHSGPZKFZCFQU-ZFNKBKEPSA-N 0.000 description 1
RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
239000000284 extract Substances 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
239000000499 gel Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
230000014509 gene expression Effects 0.000 description 1
BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
208000014674 injury Diseases 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
230000001678 irradiating effect Effects 0.000 description 1
239000008101 lactose Substances 0.000 description 1
XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
244000144972 livestock Species 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 1
XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
244000005700 microbiome Species 0.000 description 1
230000003228 microsomal effect Effects 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
239000007968 orange flavor Substances 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
238000002638 palliative care Methods 0.000 description 1
QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000008024 pharmaceutical diluent Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000000207 pro-atherogenic effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
238000000746 purification Methods 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
238000010992 reflux Methods 0.000 description 1
230000007017 scission Effects 0.000 description 1
ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
239000004208 shellac Substances 0.000 description 1
229940113147 shellac Drugs 0.000 description 1
235000013874 shellac Nutrition 0.000 description 1
238000010898 silica gel chromatography Methods 0.000 description 1
230000000391 smoking effect Effects 0.000 description 1
235000017550 sodium carbonate Nutrition 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
238000007614 solvation Methods 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000003206 sterilizing agent Substances 0.000 description 1
239000006190 sub-lingual tablet Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
239000007916 tablet composition Substances 0.000 description 1
239000006208 topical dosage form Substances 0.000 description 1
CMSGWTNRGKRWGS-NQIIRXRSSA-N torcetrapib Chemical compound COC(=O)N([C@H]1C[C@@H](CC)N(C2=CC=C(C=C21)C(F)(F)F)C(=O)OCC)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 CMSGWTNRGKRWGS-NQIIRXRSSA-N 0.000 description 1
208000019553 vascular disease Diseases 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Obesity (AREA)
Hematology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Child & Adolescent Psychology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Quinoline Compounds (AREA)
Cephalosporin Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

OA1200200158A 1999-11-30 2000-11-14 4-Carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinolinecrystal as CETP inhibitor. OA12099A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US16805199P	1999-11-30	1999-11-30

Publications (1)

Publication Number	Publication Date
OA12099A true OA12099A (en)	2006-05-04

Family

ID=22609901

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200200158A OA12099A (en)	1999-11-30	2000-11-14	4-Carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinolinecrystal as CETP inhibitor.

Country Status (28)

Country	Link
EP (1)	EP1246804A1 (fr)
JP (1)	JP2003515592A (fr)
KR (1)	KR20020058057A (fr)
CN (1)	CN1402711A (fr)
AP (1)	AP2002002531A0 (fr)
AU (1)	AU1048801A (fr)
BG (1)	BG106854A (fr)
BR (1)	BR0015836A (fr)
CA (1)	CA2392979A1 (fr)
CO (1)	CO5271716A1 (fr)
EA (1)	EA200200510A1 (fr)
EC (1)	ECSP003792A (fr)
EE (1)	EE200200277A (fr)
GT (1)	GT200000199A (fr)
HU (1)	HUP0203521A2 (fr)
IL (1)	IL149097A0 (fr)
IS (1)	IS6338A (fr)
MA (1)	MA26845A1 (fr)
MX (1)	MXPA02005354A (fr)
NO (1)	NO20022558L (fr)
OA (1)	OA12099A (fr)
PA (1)	PA8506301A1 (fr)
PE (1)	PE20010904A1 (fr)
PL (1)	PL355892A1 (fr)
TN (1)	TNSN00231A1 (fr)
TR (1)	TR200201446T2 (fr)
UY (1)	UY26454A1 (fr)
WO (1)	WO2001040190A1 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7115279B2 (en)	2000-08-03	2006-10-03	Curatolo William J	Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
HUP0400263A2 (hu) *	2001-06-21	2005-03-29	Pfizer Products Inc.	Koleszteril-észter transzfer protein inhibitort tartalmazó önemulgeáló készítmény
GT200200170A (es)	2001-09-28	2003-05-23		Preparacion de inhibidor de cetp anhidro
MXPA04007433A (es) *	2002-02-01	2004-10-11	Pfizer Prod Inc	Procedimiento para preparar dispersiones solidas amorfas homogeneas de farmaco secadas por pulverizacion utilizando un dispositivo de secado por pulverizacion modificado.
EP1920766B1 (fr) *	2002-02-01	2017-08-23	Bend Research, Inc	Compositions pharmaceutiques de dispersions amorphes de médicaments et matériaux formant des microphases lipophiles
JP2005523262A (ja)	2002-02-01	2005-08-04	ファイザー・プロダクツ・インク	薬物及び親油性ミクロ相形成物質の非晶質分散物の医薬組成物
ES2277142T3 (es)	2002-08-30	2007-07-01	Japan Tobacco Inc.	Compuesto de dibencilamina y su uso medicinal.
MXPA05003456A (es)	2002-10-04	2005-07-05	Millennium Pharm Inc	Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias.
US7504508B2 (en)	2002-10-04	2009-03-17	Millennium Pharmaceuticals, Inc.	PGD2 receptor antagonists for the treatment of inflammatory diseases
US20040132771A1 (en) *	2002-12-20	2004-07-08	Pfizer Inc	Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
ATE407670T1 (de)	2002-12-20	2008-09-15	Pfizer Prod Inc	Dosierungsform enthaltend einen cetp-hemmer und einen hmg-coa reduktase hemmer
CA2519458A1 (fr)	2003-03-17	2004-09-30	Japan Tobacco Inc.	Procede pour accroitre la biodisponibilite orale de s- 2-( '1-(2-ethylbutyl)cyclohexyl!carbonyl!amino)phenyl!-2-methylpropanethioate
BRPI0408897A (pt) *	2003-03-28	2006-04-18	Pfizer Prod Inc	derivados de 1,2,3,4-tetrahidro-e 1,2-dihidro-quinolina 1,2,4-substituìdos como inibidores de cetp para o tratamento de arteroesclerose e obesidade
ATE540671T1 (de)	2003-08-04	2012-01-15	Bend Res Inc	Pharmazeutische zusammensetzungen von adsorbaten von amorphen arzneimitteln und lipophilen mikrophasen-bildenden materialien
BRPI0414186A (pt)	2003-10-08	2006-10-31	Lilly Co Eli	compostos, métodos de antagonizar a atividade de cetp, de tratar ou prevenir uma doença, de diminuir o colesterol ldl plasmático em um mamìmero, de tratar e/ou prevenir seqüelas patológicas, formulação farmacêutica, e, uso de um composto
AU2005233160B2 (en) *	2004-04-13	2011-06-02	Merck Sharp & Dohme Corp.	CETP inhibitors
CA2570688A1 (fr) *	2004-06-24	2006-02-02	Eli Lilly And Company	Composes et procedes destines a traiter la dyslipidemie
WO2006033004A1 (fr) *	2004-09-23	2006-03-30	Pfizer Products Inc.	Composes de quinoline en tant qu'inhibiteurs de cetp
WO2006033001A1 (fr) *	2004-09-23	2006-03-30	Pfizer Products Inc.	Composes de quinoline
AU2006216713A1 (en)	2005-02-24	2006-08-31	Millennium Pharmaceuticals, Inc.	PGD2 receptor antagonists for the treatment of inflammatory diseases
WO2006098394A1 (fr) *	2005-03-14	2006-09-21	Japan Tobacco Inc.	Méthode pour inhiber l’absorption de lipides et l’inhibiteur de l'absorption de lipides
US7737155B2 (en)	2005-05-17	2010-06-15	Schering Corporation	Nitrogen-containing heterocyclic compounds and methods of use thereof
AR065670A1 (es)	2007-03-09	2009-06-24	Indigene Pharmaceuticals Inc	Combinacion de metformina r-(+) lipoato y agentes antihiperlipidemicos para el tratamiento de hiperglucemia diabetica y complicaciones diabeticas
EP2379547A1 (fr)	2008-12-16	2011-10-26	Schering Corporation	Dérivés de pyridopyrimidine et leurs procédés d'utilisation
WO2010075069A1 (fr)	2008-12-16	2010-07-01	Schering Corporation	Dérivés de pyranone bicycliques en tant qu'agonistes des récepteurs nicotiniques
TWI450896B (zh)	2009-06-30	2014-09-01	Lilly Co Eli	反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸
JP6854752B2 (ja)	2014-07-30	2021-04-07	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	Ｈｄｌ上昇剤又はｈｄｌ模倣剤を用いた治療に対する応答性を予測するための遺伝マーカー

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5231102A (en) *	1989-03-08	1993-07-27	Merck Sharp & Dohme, Ltd.	Tetrahydroquinoline derivatives useful for neurodegenerative disorders
WO1998033775A1 (fr) *	1997-02-03	1998-08-06	American Home Products Corporation	Derives de l'-1-acyl-1,2-dihydroquinoline substituee en 2 augmentant la concentration en cholesterol hdl
US6197786B1 (en) *	1998-09-17	2001-03-06	Pfizer Inc	4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines

2000
- 2000-11-09 CO CO00085285A patent/CO5271716A1/es unknown
- 2000-11-13 PA PA20008506301A patent/PA8506301A1/es unknown
- 2000-11-14 BR BR0015836-4A patent/BR0015836A/pt not_active IP Right Cessation
- 2000-11-14 KR KR1020027006914A patent/KR20020058057A/ko not_active Ceased
- 2000-11-14 EP EP00971662A patent/EP1246804A1/fr not_active Withdrawn
- 2000-11-14 HU HU0203521A patent/HUP0203521A2/hu unknown
- 2000-11-14 EE EEP200200277A patent/EE200200277A/xx unknown
- 2000-11-14 CA CA002392979A patent/CA2392979A1/fr not_active Abandoned
- 2000-11-14 MX MXPA02005354A patent/MXPA02005354A/es unknown
- 2000-11-14 TR TR2002/01446T patent/TR200201446T2/xx unknown
- 2000-11-14 AP APAP/P/2002/002531A patent/AP2002002531A0/en unknown
- 2000-11-14 JP JP2001541875A patent/JP2003515592A/ja active Pending
- 2000-11-14 AU AU10488/01A patent/AU1048801A/en not_active Abandoned
- 2000-11-14 IL IL14909700A patent/IL149097A0/xx unknown
- 2000-11-14 WO PCT/IB2000/001650 patent/WO2001040190A1/fr not_active Ceased
- 2000-11-14 EA EA200200510A patent/EA200200510A1/ru unknown
- 2000-11-14 PL PL00355892A patent/PL355892A1/xx not_active Application Discontinuation
- 2000-11-14 OA OA1200200158A patent/OA12099A/en unknown
- 2000-11-14 CN CN00816463A patent/CN1402711A/zh active Pending
- 2000-11-28 PE PE2000001267A patent/PE20010904A1/es not_active Application Discontinuation
- 2000-11-28 UY UY26454A patent/UY26454A1/es not_active Application Discontinuation
- 2000-11-29 TN TNTNSN00231A patent/TNSN00231A1/fr unknown
- 2000-11-29 GT GT200000199A patent/GT200000199A/es unknown
- 2000-11-29 EC EC2000003792A patent/ECSP003792A/es unknown
2002
- 2002-04-12 IS IS6338A patent/IS6338A/is unknown
- 2002-05-27 MA MA26653A patent/MA26845A1/fr unknown
- 2002-05-29 NO NO20022558A patent/NO20022558L/no not_active Application Discontinuation
- 2002-06-20 BG BG106854A patent/BG106854A/bg unknown

Also Published As

Publication number	Publication date
AU1048801A (en)	2001-06-12
HUP0203521A2 (hu)	2003-02-28
KR20020058057A (ko)	2002-07-12
PE20010904A1 (es)	2001-09-10
BG106854A (bg)	2002-12-29
CO5271716A1 (es)	2003-04-30
EE200200277A (et)	2003-10-15
NO20022558D0 (no)	2002-05-29
MA26845A1 (fr)	2004-12-20
ECSP003792A (es)	2002-04-23
PL355892A1 (en)	2004-05-31
IS6338A (is)	2002-04-12
MXPA02005354A (es)	2002-12-11
GT200000199A (es)	2002-05-23
TNSN00231A1 (fr)	2002-05-30
WO2001040190A1 (fr)	2001-06-07
AP2002002531A0 (en)	2002-06-30
UY26454A1 (es)	2001-07-31
CN1402711A (zh)	2003-03-12
PA8506301A1 (es)	2002-08-26
TR200201446T2 (tr)	2002-11-21
IL149097A0 (en)	2002-11-10
BR0015836A (pt)	2002-08-06
NO20022558L (no)	2002-05-29
JP2003515592A (ja)	2003-05-07
CA2392979A1 (fr)	2001-06-07
EP1246804A1 (fr)	2002-10-09
EA200200510A1 (ru)	2002-10-31

Publication	Publication Date	Title
OA12099A (en)	2006-05-04	4-Carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinolinecrystal as CETP inhibitor.
US6313142B1 (en)	2001-11-06	Method for making 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinoline
AU2002358585A1 (en)	2003-06-17	Acetylene derivatives having mglur 5 antagonistic activity
KR20170102204A (ko)	2017-09-08	테트라하이드로퀴놀린 유도체 제조용의 합성 중간체를 제조하기 위한 방법
PL108111B1 (pl)	1980-03-31	Method of producing optically active antipodes of sposob wytwarzania optycznie czynnych antypodow n-n-/2-benzhydryloethylo/-n-/1-phenyloethylo/amines /2-benzhydryloetylo/-n-/1-fenyloetylo-/amin,i ich soli and salts thereof
PT87277B (pt)	1992-08-31	Processo para a preparacao de novos compostos biciclicos e composicoes farmaceuticas compreendendo os mesmos
DE69105786T2 (de)	1995-04-27	Harnstoffderivate, deren Herstellung sowie diese enthaltende pharmazeutische Zusammensetzungen.
ZA200600156B (en)	2007-04-25	Tacrine derivatives as inhibitors of acetylcholinesterase
CN107522766B (zh)	2020-03-27	一类具有抗肿瘤活性的熊果酸喹啉基酰肼衍生物及其制备方法和应用
GB2098205A (en)	1982-11-17	Indoles
RU2176639C2 (ru)	2001-12-10	Новые гетероарилоксиэтиламины, способ их получения, содержащая их фармацевтическая композиция, обладающая сродством к 5нт1a рецепторам, промежуточные соединения
CA2090635A1 (fr)	1993-09-04	Derives phenylquinazoline substitues
MXPA00011855A (en)	2002-06-05	Method for making (-)-(2r,4s)-4- [(3,5-bis- trifluoromethyl-benzyl)- methoxycarbonylamino]- 2-ethyl-6- trifluoromethyl-3,4-dihydro- 2h-quinoline- 1-carboxylic acid ethyl ester
HK1038007B (en)	2005-04-08	Method for making 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinoline
WO1997005114A1 (fr)	1997-02-13	Sulfimides de quinolone ayant une action antagoniste sur les leucotrienes
BE550426A (fr)